PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsThalidomide
Thalomid, Thalidomide bms (previously thalidomide celgene)(thalidomide)
Thalidomide, Thalomid (thalidomide) is a small molecule pharmaceutical. Thalidomide was first approved as Thalomid on 1998-07-16. It is used to treat aphthous stomatitis, behcet syndrome, crohn disease, discoid lupus erythematosus, and erythema multiforme amongst others in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target protein cereblon.
Download report
Favorite
SARS-CoV-2 Interaction
BMS
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
musculoskeletal diseasesD009140
digestive system diseasesD004066
stomatognathic diseasesD009057
respiratory tract diseasesD012140
eye diseasesD005128
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
Show 4 more
Trade Name
FDA
EMA
Thalomid (discontinued: Thalidomide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Thalidomide
Tradename
Company
Number
Date
Products
THALOMIDBristol Myers SquibbN-020785 RX1998-07-16
4 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
thalomidNew Drug Application2023-03-24
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AX: Other immunosuppressants in atc
L04AX02: Thalidomide
HCPCS
No data
Clinical
Clinical Trials
538 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple myelomaD009101C90.0279461417186
Plasma cell neoplasmsD054219268758416175
LymphomaD008223C85.942532234
SyndromeD01357721921124
Myelodysplastic syndromesD009190D4631421221
PreleukemiaD0112893142119
Non-small-cell lung carcinomaD0022892113115
Lung neoplasmsD008175C34.90293114
ThalassemiaD013789EFO_1001996D561841112
AmyloidosisD000686EFO_1001875E851711110
Show 31 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80915527
LeukemiaD007938C954182324
PlasmacytomaD010954C90.31145121
CarcinomaD002277C80.03146117
Liver neoplasmsD008113EFO_1001513C22.02146117
Hepatocellular carcinomaD006528C22.02116114
Prostatic neoplasmsD011471C61112113
Crohn diseaseD003424EFO_0000384K5012349
Primary myelofibrosisD055728D47.4628
Colorectal neoplasmsD0151791618
Show 44 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell chronic lymphocytic leukemiaD015451C91.1411113
Central nervous system neoplasmsD01654321113
Nervous system neoplasmsD00942311112
Hiv infectionsD015658EFO_0000764B2027312
RecurrenceD01200810111
Non-hodgkin lymphomaD008228C85.949111
MelanomaD0085453911
Lymphoid leukemiaD007945C912819
SarcomaD01250988
GliomaD005910EFO_0000520268
Show 138 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients55
Therapeutic equivalencyD01381022
LiposarcomaD00808011
Intestinal neoplasmsD007414C26.011
Pulmonary sarcoidosisD017565DOID_13406D86.011
OsteosarcomaD01251611
RetinoblastomaD01217511
Ewing sarcomaD012512EFO_000017311
RhabdomyosarcomaD01220811
Primitive neuroectodermal tumorsD01824211
Show 7 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hematopoietic stem cell transplantationD01838033
Bone marrow transplantationD01602611
AdrenoleukodystrophyD000326Orphanet_43E71.5211
MothersD00903511
Carpal tunnel syndromeD002349EFO_0004143G56.011
LeukapheresisD00793711
Acute-phase reactionD00021011
SurvivorshipD00007385911
Chronic painD05935011
TendinopathyD052256EFO_1001434M77.911
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameThalidomide
INNthalidomide
Description
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione is a dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group. It is a member of piperidones and a member of phthalimides.
Classification
Small molecule
Drug classthalidomide derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1
Identifiers
PDB
CAS-ID1012310-87-0
RxCUI
ChEMBL IDCHEMBL468
ChEBI ID74947
PubChem CID5426
DrugBankDB01041
UNII ID4Z8R6ORS6L (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CRBN
CRBN
Organism
Homo sapiens
Gene name
CRBN
Gene synonyms
NCBI Gene ID
Protein name
protein cereblon
Protein synonyms
protein x 0001
Uniprot ID
Mouse ortholog
Crbn (58799)
protein cereblon (Q8C7D2)
Variants
No data
Financial
Revenue by drug
$
£
Thalomid Celgene
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 62,688 documents
View more details
Safety
Black-box Warning
Black-box warning for: Thalomid
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
37,831 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use